Abstract
Cytokines have the potential to be the ideal biomarkers to track the onset and progression of immune-mediated diseases, study the development of novel therapeutic strategies, and they can serve as outcome parameters due to their crucial role in the regulation of immune and inflammatory responses. It is vital to keep track of the entire cytokine spectrum due to the complex interactions, pleiotropic effects, and redundancy in the cytokine network. The multiplex immunoassay (MIA) is, therefore, the best method for achieving that goal. This chapter addresses the key methodological processes of this technique, such as sample preparation, antibody coupling to beads, and assay procedure.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Stephenson J, Nutma E, van der Valk P, Amor S (2018) Inflammation in CNS neurodegenerative diseases. Immunology 154:204–219
Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129:154–169
Gaetani L, Paolini Paoletti F, Bellomo G, Mancini A, Simoni S, Di Filippo M, Parnetti L (2020) CSF and blood biomarkers in neuroinflammatory and neurodegenerative diseases: implications for treatment. Trends Pharmacol Sci 41:1023–1037
Huang S, Wang YJ, Guo J (2022) Biofluid biomarkers of Alzheimer’s disease: progress, problems, and perspectives. Neurosci Bull 38:677–691
Ferreira D, Perestelo-Pérez L, Westman E, Wahlund LO, Sarría A, Serrano-Aguilar P (2014) Meta-review of CSF core biomarkers in Alzheimer’s disease: the state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci 6:47
Angiulli F, Conti E, Zoia CP (2021) Blood-based biomarkers of neuroinflammation in Alzheimer’s disease: a central role for periphery? Diagnostics (Basel) 11:1525
Clark C, Richiardi J, Maréchal B (2022) Systemic and central nervous system neuroinflammatory signatures of neuropsychiatric symptoms and related cognitive decline in older people. J Neuroinflammation 19:127
Hampel H, O’Bryant SE, Molinuevo JL, Zetterberg H, Masters CL, Lista S, Kiddle SJ, Batrla R, Blennow K (2018) Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 14:639–652
Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer’s disease: challenging but feasible. Biomark Med 4:65–79
Galasko D, Golde TE (2013) Biomarkers for Alzheimer’s disease in plasma, serum and blood-conceptual and practical problems. Alzheimers Res Ther 5:10
Srivastava A, Dixit AB, Paul D, Tripathi M, Sarkar C, Chandra PS, Banerjee J (2017) Comparative analysis of cytokine/chemokine regulatory networks in patients with hippocampal sclerosis (HS) and focal cortical dysplasia (FCD). Sci Rep 7:15904
Kan AA, de Jager W, de Wit M et al (2012) Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines. J Neuroinflammation 9:207
Barroeta-Espar I, Weinstock LD, Perez-Nievas BG, Meltzer AC, Siao Tick Chong M, Amaral AC, Murray ME, Moulder KL, Morris JC, Cairns NJ, Parisi JE, Lowe VJ, Petersen RC, Kofler J, Ikonomovic MD, López O, Klunk WE, Mayeux RP, Frosch MP, Wood LB, Gomez-Isla T (2019) Distinct cytokine profiles in human brains resilient to Alzheimer’s pathology. Neurobiol Dis 121:327–337
Ahsan H (2022) Monoplex and multiplex immunoassays: approval, advancements, and alternatives. Comp Clin Pathol 31:333–345
Zheng W, He L (2012) Multiplexed immunoassays. Advances in immunoassay technology. Edited by Norman H. L. Chiu and Theodore K. Christopoulos Ahsan H (2019) The biomolecules of beauty: biochemical pharmacology and immunotoxicology of cosmeceuticals. J Immunoassay Immunochem 40:91–108
Ahsan H (2019) The biomolecules of beauty: biochemical pharmacology and immunotoxicology of cosmeceuticals. J Immunoassay Immunochem 40:91–108
Fu Q, Zhu J, Van Eyk JE (2010) Comparison of multiplex immunoassay platforms. Clin Chem 56:314–318
Houser B (2012) Bio-Rad’s Bio-Plex(R) suspension array system, xMAP technology overview. Arch Physiol Biochem 118:192–196
Hidese S, Hattori K, Sasayama D (2021) Cerebrospinal fluid inflammatory cytokine levels in patients with major psychiatric disorders: a multiplex immunoassay study. Front Pharmacol 11:594394
Belzeaux R, Lefebvre MN, Lazzari A, Le Carpentier T, Consoloni JL, Zendjidjian X (2017) How to: measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays. Psychoneuroendocrinology 75:72–82
Jane LA, Wray AA (2022) Lumbar puncture. [Updated 2022 July 25]. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557553/
Acknowledgments
This work is funded by the MEG resource facility, funded by the Department of Biotechnology, Ministry of Science and Technology, Govt. of India [BT/MED/122/SP24580/2018].
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Srivastava, A., Dixit, A.B., Tripathi, M., Sarat Chandra, P., Banerjee, J. (2024). Quantification of Neuroinflammatory Markers in Blood, Cerebrospinal Fluid, and Resected Brain Samples Obtained from Patients. In: Ray, S.K. (eds) Neuroprotection. Methods in Molecular Biology, vol 2761. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3662-6_6
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3662-6_6
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3661-9
Online ISBN: 978-1-0716-3662-6
eBook Packages: Springer Protocols